Name | APTEKA N42, OOO |
|---|
INN | 0530010406 |
|---|
KPP | 053001001 |
|---|
OGRN | 1110550000670 |
|---|
OKPO | 25210419 |
|---|
Address | 368650, Respublika Dagestan, r-n Tabasaranskiy, s. Khuchni, ul. Naberezhnaya, d. D.46 |
|---|
Phone | Contact details |
|---|
|
| OKVED code | Type | Name of activity type |
|---|
| 47.73 | Core activity | Retailing drugs in specialized stores (pharmacies) | | 47.74 | Additional activity | Retailing products used for medical purposes, orthopedic goods in specialized stores | | 47.75 | Additional activity | Retailing of cosmetics and personal hygiene products in specialized stores |
Registration date | 25.11.2011 |
|---|
|
APTEKA N42, OOO (Dagestan, Republic; INN 0530010406) was registered on 25 Nov 2011. The company's authorized capital as of July 1, 2012 was 10000 rub. Principal activities of APTEKA N42, OOO: retailing drugs in specialized stores (pharmacies) (47.73), retailing products used for medical purposes, orthopedic goods in specialized stores (47.74), retailing of cosmetics and personal hygiene products in specialized stores (47.75). |
Economic indicators2023
Net profit (RAS) of APTEKA N42, OOO dropped in 2023 by 1.96% to 10.27 million RUB from 10.47 million RUB over the same period in 2022, the company informed. Revenue decreased in the accounting period by 17.55% to 39.84 million RUB from 48.32 million RUB in 2022; cost of goods sold decreased by 21.86% to 29.58 million RUB from 37.85 million RUB; sales profit fell by 1.96% to 10.27 million RUB from 10.47 million RUB. 2022
Net profit (RAS) of APTEKA N42, OOO grew over 2022 6.10 times to 10.47 million RUB from 1.72 million RUB over 2021, the company informed. Revenue increased in the accounting period by 14.25% to 48.32 million RUB from 42.30 million RUB over 2021; cost of goods sold decreased by 6.72% to 37.85 million RUB from 40.58 million RUB; sales profit went up 6.10 times to 10.47 million RUB from 1.72 million RUB. 2021
Net profit (RAS) of APTEKA N42, OOO grew over 2021 by 15.01% to 1.72 million RUB from 1.49 million RUB over 2020, the company informed. Revenue increased in the accounting period 1.84 times to 42.30 million RUB from 22.95 million RUB over 2020; cost of goods sold grew 1.89 times to 40.58 million RUB from 21.46 million RUB; sales profit went up by 15.01% to 1.72 million RUB from 1.49 million RUB. 2020
Net profit (RAS) of APTEKA N42, OOO grew over 2020 by 33.35% to 4.59 million RUB from 3.44 million RUB over 2019, the company informed. Revenue increased in the accounting period by 33.35% to 22.95 million RUB from 17.21 million RUB over 2019; cost of goods sold grew by 33.35% to 18.36 million RUB from 13.77 million RUB; sales profit went up by 33.35% to 4.59 million RUB from 3.44 million RUB. 2019
Net profit (RAS) of APTEKA N42, OOO dropped in 2019 by 1.52% to 3.44 million RUB from 3.50 million RUB over the same period in 2018, the company informed. Revenue increased in the accounting period by 0.93% to 17.21 million RUB from 17.05 million RUB over 2018; cost of goods sold grew by 1.56% to 13.77 million RUB from 13.56 million RUB; sales profit fell by 1.52% to 3.44 million RUB from 3.50 million RUB. 2018
Net profit (RAS) of APTEKA N42, OOO dropped in 2018 by 34.00% to 3.15 million RUB from 4.77 million RUB over the same period in 2017, the company informed. Revenue decreased in the accounting period by 35.17% to 17.05 million RUB from 26.30 million RUB in 2017; cost of goods sold decreased by 35.46% to 13.56 million RUB from 21.00 million RUB; sales profit fell by 34.06% to 3.50 million RUB from 5.30 million RUB. 2017
Net profit (RAS) of APTEKA N42, OOO grew over 2017 by 21.68% to 4.77 million RUB from 3.92 million RUB over 2016, the company informed. Revenue increased in the accounting period by 21.50% to 26.30 million RUB from 21.65 million RUB over 2016; cost of goods sold grew by 21.42% to 21.00 million RUB from 17.30 million RUB; sales profit went up by 21.81% to 5.30 million RUB from 4.35 million RUB.
unlimited access to database "Kontragent" download any information within 24 hours
Companies in the region
|